Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17289288 | 1.00 | CYP3A4 (0.60) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL17289296 | 1.00 | CYP3A4 (0.60) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL22512408 | 0.89 | CYP3A4 (0.60) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL15833950 | 0.87 | CYP3A4 (0.53) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL23498913 | 0.87 | CYP3A4 (0.57) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL15825618 | 0.87 | CYP3A4 (0.57) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL2059305 | 0.85 | PTGS1 (0.64) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL17289308 | 0.85 | CYP3A4 (0.55) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL30534604 | 0.85 | CYP3A4 (0.67) | CYP3A4TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL10367354 | 0.85 | CYP3A4 (0.67) | CYP3A4TSHRPTGS1PTGS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170892-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAGAMAGE | SULFATEQ B.V. (NL) | 2018-06-21 | — | — | US | claimed |
| EP-3297625-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | Sulfateq B.V. (NL) | 2018-03-28 | — | — | EP | claimed |
| US-20170151234-A1 | 6-Hydroxy-2,5,7,8-Tetramethylchroman-Compounds for the Treatment of Chronic Obstructive Airway Diseases | SULFATEQ B.V. (NL) | 2017-06-01 | — | — | US | claimed |
| EP-3157518-A1 | 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASES | Sulfateq B.V. (NL) | 2017-04-26 | — | — | EP | claimed |
| WO-2016188766-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | SULFATEQ B.V. (NL) | 2016-12-01 | — | — | WO | claimed |
| WO-2015193365-A1 | 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASES | SULFATEQ B.V. (NL) | 2015-12-23 | — | — | WO | claimed |
| EP-3388426-B1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ BV (NL) | 2023-07-05 | — | — | EP | disclosed |
| EP-3388426-B1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ BV (NL) | 2023-07-05 | — | — | EP | disclosed |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-11006626-B2 | Compounds for protection of cells | SULFATEQ B.V. (NL) | 2021-05-18 | — | — | US | disclosed |
| US-11006626-B2 | Compounds for protection of cells | SULFATEQ B.V. (NL) | 2021-05-18 | — | — | US | disclosed |
| CN-107660148-B | Compounds for preventing or treating organ damage | 萨尔法泰克有限公司 | 2021-03-09 | — | — | CN | disclosed |
| WO-2015193365-A1 | 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASES | SULFATEQ B.V. (NL) | 2015-12-23 | — | — | WO | disclosed |
| US-20150342174-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150342174-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150342174-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| EP-2935232-A1 | COMPOUNDS FOR PROTECTION OF CELLS | Sulfateq B.V. (NL) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014098586-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014098586-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151234-A1 | 6-Hydroxy-2,5,7,8-Tetramethylchroman-Compounds for the Treatment of Chronic Obstructive Airway Diseases | HRH4, CFTR, HRH2 | CYP3A4 1552/4885TSHR 3140/4885PTGS1 211/4885 |
| US-11006626-B2 | Compounds for protection of cells | CASP10, BAX, CASP9 | CYP3A4 2558/4885TSHR 1062/4885PTGS1 1184/4885 |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | CYP3A4 2558/4885TSHR 1062/4885PTGS1 1184/4885 |
| US-20150342174-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | CYP3A4 2558/4885TSHR 1062/4885PTGS1 1184/4885 |
| US-20180170892-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAGAMAGE | LIPG, GLS, TXN2 | CYP3A4 1933/4885TSHR 3910/4885PTGS1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.